Merck
  • Home
  • Search Results
  • Abnormal fatty acid metabolism in patients in hopantenate therapy during clinical episodes.

Abnormal fatty acid metabolism in patients in hopantenate therapy during clinical episodes.

Journal of chromatography (1991-01-02)
M Matsumoto, T Kuhara, Y Inoue, T Shinka, I Matsumoto
ABSTRACT

Calcium 4-(2,4-dihydroxy-3,3-dimethylbutyramido)butyrate hemihydrate (hopantenate), a cerebral metabolic enhancer used in Japan since 1978, is a homologue of pantothenic acid. Using mass spectrometry, we found urinary excretion of 4-hydroxydodecanedioic acid, 4-hydroxytetradecanedioic acid and a series of 2-hydroxydicarboxylic acids (C8-C14), in addition to a series of odd- and even-numbered dicarboxylic acids (C5-C12) and 3-hydroxydicarboxylic acids (C8-C14) in patients receiving hopantenate during episodes of Reye's-like syndrome. Our findings suggest that an acute intoxication associated with hopantenate occurs owing to pantothenic acid deficiency or the inhibition of CoA-requiring reactions during stress, i.e. infection, prolonged fasting, or malnutrition.

MATERIALS
Product Number
Brand
Product Description

Supelco
Adipic acid, certified reference material, TraceCERT®
Sigma-Aldrich
Adipic acid, 99%
Sigma-Aldrich
Adipic acid, BioXtra, ≥99.5% (HPLC)
Sigma-Aldrich
Adipic acid, ≥99.5%